137 related articles for article (PubMed ID: 29870646)
21. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
22. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
23. Update on therapeutic options for multiple sclerosis.
McCoyd M
Neurol Clin; 2013 Aug; 31(3):827-45. PubMed ID: 23896508
[TBL] [Abstract][Full Text] [Related]
24. Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
Rolla S; De Mercanti SF; Bardina V; Horakova D; Habek M; Adamec I; Cocco E; Annovazzi P; Vladic A; Novelli F; Durelli L; Clerico M
J Neuroimmunol; 2017 Dec; 313():89-91. PubMed ID: 29153614
[TBL] [Abstract][Full Text] [Related]
25. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
26. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
27. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
28. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
Richter S; Wagner B; Celius EG
J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
[No Abstract] [Full Text] [Related]
29. Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.
Frau J; Coghe G; Fenu G; Lorefice L; Cocco E
Neurol Sci; 2018 Feb; 39(2):389-390. PubMed ID: 28986705
[No Abstract] [Full Text] [Related]
30. [Current immunotherapy of multiple sclerosis].
Paul F; Ruprecht K
Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
[TBL] [Abstract][Full Text] [Related]
31. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
32. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
33. [MODERN APPROACHES TO THE TREATMENT OF MULTIPLE SCLEROSIS (REVIEW AND CLINICAL CASE)].
Khamidulla A; Kabdrakhmanova G; Utepkaliyeva A; Darin D; Urasheva Z
Georgian Med News; 2018 May; (278):93-83. PubMed ID: 29905552
[TBL] [Abstract][Full Text] [Related]
34. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
35. Towards a More User-Friendly Medication Information Delivery to People Living with Multiple Sclerosis: A Case Study with Alemtuzumab.
Azman A; Poyade M; Overell J
Adv Exp Med Biol; 2019; 1120():67-82. PubMed ID: 30919295
[TBL] [Abstract][Full Text] [Related]
36. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
37. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
[TBL] [Abstract][Full Text] [Related]
38. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
[TBL] [Abstract][Full Text] [Related]
39. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies.
Holmøy T; von der Lippe H; Leegaard TM
BMC Neurol; 2017 Apr; 17(1):65. PubMed ID: 28376817
[TBL] [Abstract][Full Text] [Related]
40. Vaccines and disease-modifying treatments.
Waubant E; Giovannoni G; Hawkes C; Levy M
Mult Scler Relat Disord; 2018 Nov; 26():A1-A2. PubMed ID: 30573174
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
